Through a series of live-cell single-molecule imaging experiments, researchers at the University of York discovered how rogue communications between cells lead to leukemia, according to a recent study published in Science.
Through a series of live-cell single-molecule imaging experiments, researchers at the University of York discovered how rogue communications between cells lead to leukemia, according to a recent study published in Science.
Using super-resolution fluorescent microscopy, researchers studied the way blood stem cells communicated in real time. Cells received instructions from signaling proteins, which bind to a receptor on the surfaces of separate cells. The proteins then transmit a signal instructing the cell how to operate.
“We quantified the dimerization of 3 prototypic class 1 cytokine receptors in the plasma membrane of living cells,” authors stated. They continued, “Spatial and spaciotemporal correlation of individual receptor subunits showed ligand-induces dimerization and revealed that the associated Janus kinase 2 (JAK2) dimerizes through its pseudokinase domain.”
The study marks the first time it has been demonstrated specific receptors on the surface of blood stem cells are linked by cytokines to form pairs, according to a press release.
Researchers hope the discovery will lead to the use of a new molecular mechanism with ligand-induced dimerization as the central switch initiating activation of these receptors. This would contradict the currently held notion of pre-dimerized, inactive receptors activated by a ligand-induced conformational change.
"Our observations led us to a previously unknown mechanism for how individual mutations trigger blood stem cells to start signaling independently of cytokines, causing the normal system to become out of control and leading to diseases like leukemia,” said Ian S. Hitchcock, PhD, an author of the study. "Understanding this mechanism may enable the identification of targets for the development of new drugs."
The study also yielded the additional findings:
Study results could also have impacts on therapeutic interventions for myeloproliferative neoplasms, other hematological malignancies, and immunological disorders.
“By directly visualizing individual receptors at physiological conditions under the microscope, we were able to resolve a controversy that has preoccupied the field for more than 20 years,” said Jacob Piehler, Phd, a coauthor of the study.
Reference
Wilmes S, Hafer M, Vuorio J, et al. Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations. Science. 2020; 367(6478):643-652. doi: 10.1126/science.aaw3242.
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma
March 7th 2024The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Read More
Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care
October 13th 2021On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.
Listen
ICYMI: Highlights From ASH 2023
December 20th 2023The most-read content from the 2023 American Society of Hematology Annual Meeting and Exposition included the latest in treating hematologic malignancies, the hope brought by novel therapy strategies, and the potential for artificial intelligence to improve diagnostic accuracy.
Read More
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
December 11th 2023Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
Read More